Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, Stefanescu C, Meyer A, Nachury M, Laharie D, Nancey S, Le Berre C, Serrero M, Geyl S, Giletta C, Ah-Soune P, Duveau N, Uzzan M, Abitbol V, Biron A, Tran-Minh ML, Paupard T, Vuitton L, Elgharabawy Y, Peyrin-Biroulet L. Fumery M, et al. Among authors: duveau n. Aliment Pharmacol Ther. 2023 Feb;57(4):426-434. doi: 10.1111/apt.17358. Epub 2022 Dec 19. Aliment Pharmacol Ther. 2023. PMID: 36534763
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Laharie D, et al. Among authors: duveau n. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2074-2082. doi: 10.1016/j.cgh.2021.11.030. Epub 2021 Nov 26. Clin Gastroenterol Hepatol. 2022. PMID: 34843987 Free article. Clinical Trial.
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.
Guillo L, Flachaire B, Avouac J, Dong C, Nachury M, Bouguen G, Buisson A, Caillo L, Fumery M, Gilletta C, Hébuterne X, Lafforgue P, Laharie D, Mahé E, Marotte H, Nancey S, Ottaviani S, Salmon JH, Savoye G, Serrero M, Uzzan M, Viguier M, Richez C, Peyrin-Biroulet L, Seksik P, Pham T; COMBIO Study Group. Guillo L, et al. Dig Liver Dis. 2023 Jan;55(1):61-68. doi: 10.1016/j.dld.2022.07.012. Epub 2022 Aug 16. Dig Liver Dis. 2023. PMID: 35985961
Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified i2 on the Rutgeerts Score.
Bayart P, Duveau N, Nachury M, Zerbib P, Gerard R, Branche J, Maunoury V, Wils P, Boruchowicz A, Boualit M, Laberenne JE, Manolache O, Desreumaux P, de Chambrun GP, Pariente B. Bayart P, et al. Among authors: duveau n. Dig Dis Sci. 2016 Oct;61(10):2986-2992. doi: 10.1007/s10620-016-4215-1. Epub 2016 Jul 11. Dig Dis Sci. 2016. PMID: 27401274
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: duveau n. Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00423-3. doi: 10.1016/j.cgh.2024.04.016. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
11 results